Share your videos with the world

Despite a decrease in lung function as you age, recent studies by researchers have concluded that to slow down this decrease lung health, you need to continue to give yourself a good dose of, Vitamin D Vitamin C Magnesium Vitamin K

New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic pulmonary fibrosis (IPF) that his father suffered from for years before he passed away in 2001. His father, Bernabé, inspired Williams to play baseball and make it to the Major Leagues, and taught him to play guitar which has become William’s second career since retiring from baseball. In honor of his father’s battle with IPF, Williams has joined the Breathless™ campaign to turn his family’s devastating experience with this rare lung disease into a chance to help other families. Williams hopes to educate and empower others who think they may have IPF to seek early diagnosis and treatment and is encouraging people to visit the campaign website – www.BreathlessIPF.com – and share the videos and educational content through social media channels such as Facebook and Twitter. To view the multimedia release go to: https://www.multivu.com/players/English/8058551-bernie-williams-ipf-breathless-campaign/

Boehringer Ingelheim announced today a new partnership with Minor League Baseball® (MiLB™) to further raise awareness of the rare lung disease idiopathic pulmonary fibrosis (IPF) through its Breathless™ campaign. Now the “Official IPF Awareness Partner of Minor League Baseball,” Boehringer Ingelheim will work with the league to educate its fan base about symptoms of IPF – and the importance of an early diagnosis and treatment – through in-stadium events as well as appearances by New York Yankees legend and musician Bernie Williams, whose father passed away from the disease in 2001. To view the multimedia release go to: https://www.multivu.com/players/English/8289951-boehringer-ingelheim-milb-partnership-for-ipf-awareness/

Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma. To view the multimedia release go to: http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/

The American Lung Association launched its first nationwide public service advertising (PSA) brand campaign in more than a decade today in an effort to raise awareness and engage people in the mission of the century-old public health charity. The campaign includes television, radio, print and out-of-home elements, all of which emphasize the American Lung Association’s brand platform and tagline, “Fighting for Air.” To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lungusa/42818/